Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JW (Cayman) Therapeutics Co. Ltd (2126.HK)
HKD1.82
+0.04 (+2.25%)
CN HKSE Healthcare Biotechnology
Address
Building B
Shanghai, CN
Shanghai, CN
CEO
Min Liu
Website
jwtherapeutics.com
IPO
2020-11-03
ISIN KYG5210T1040
Also trades on
Hong Kong Stock Exchange · 2126.HK (HKD)
Other OTC · JWCTF (USD)
Description
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD1.82
+0.04 (+2.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
947.9K
Beta
1.91
Float Shares
318.81M
Free Float %
76.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.45% | -1.98% | -15.02% | -10.00% | -36.54% | -21.12% | -0.50% | -33.33% | -93.20% | -91.00% | -91.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.82
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-9.59
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+74.6% ★ Q4'25: +102.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+9.1% Q4'25: +27.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-41.6% Q4'25: -13.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-87.5% Q4'25: -102.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-76.5% Q4'25: -226.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q4'25: +1.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.62× Q4'25: -0.47× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
30.80M
est: 115.92M (-73.4%)
|
145.70M
est: 169.40M (-14.0%)
|
173.86M
est: 160.86M (+8.1%)
|
158.22M
est: 183.27M (-13.7%)
|
276.31M
est: 243.63M (+13.4%)
|
323.97M
323.97M – 323.97M
+33.0% YoY
|
839.98M
839.98M – 839.98M
+159.3% YoY
|
511.08M
511.08M – 511.08M
-39.2% YoY
|
| EBITDA |
-738.70M
est: -69.55M (-962.1%)
|
-752.27M
est: -101.64M (-640.2%)
|
-655.75M
est: -147.55M (-344.4%)
|
-381.58M
est: -168.10M (-127.0%)
|
-161.95M
est: -223.46M (+27.5%)
|
-297.16M
-297.16M – -297.16M
-33.0% YoY
|
-770.45M
-770.45M – -770.45M
-159.3% YoY
|
-468.77M
-468.77M – -468.77M
+39.2% YoY
|
| EBIT |
-771.72M
est: -69.55M (-1,009.6%)
|
-839.35M
est: -101.64M (-725.8%)
|
-755.58M
est: -156.83M (-381.8%)
|
-459.03M
est: -178.68M (-156.9%)
|
-241.71M
est: -237.53M (-1.8%)
|
-315.86M
-315.86M – -315.86M
-33.0% YoY
|
-818.94M
-818.94M – -818.94M
-159.3% YoY
|
-498.28M
-498.28M – -498.28M
+39.2% YoY
|
| Net Income |
-702.33M
est: -544.78M (-28.9%)
|
-846.14M
est: -617.70M (-37.0%)
|
-768.00M
est: -588.67M (-30.5%)
|
-590.62M
est: -731.51M (+19.3%)
|
-540.92M
est: -428.08M (-26.4%)
|
-332.04M
-332.04M – -332.04M
+22.4% YoY
|
-210.85M
-210.85M – -210.85M
+36.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
372.25M
est: 399.35M (-6.8%)
|
370.64M
est: 583.60M (-36.5%)
|
117.75M
est: 547.52M (-78.5%)
|
145.16M
est: 623.80M (-76.7%)
|
219.00M
est: 829.24M (-73.6%)
|
1.10B
1.10B – 1.10B
+33.0% YoY
|
2.86B
2.86B – 2.86B
+159.3% YoY
|
1.74B
1.74B – 1.74B
-39.2% YoY
|
| EPS |
-1.76
est: -1.32 (-33.6%)
|
-2.06
est: -1.49 (-37.9%)
|
-1.87
est: -1.42 (-32.1%)
|
-1.43
est: -1.76 (+18.7%)
|
-1.30
est: -1.03 (-26.3%)
|
-0.80
-0.80 – -0.80
+22.4% YoY
|
-0.51
-0.51 – -0.51
+36.5% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-197.67M
OE per share TTM
-0.48
Owner's Yield
-24.00%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
267.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 49.8K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.01% | 27.2K | 0.59% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-860.2K
Shares Outstanding
416.47M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yiping Li | Co-Founder & Director | 6M | — |
| Min Liu | Chief Executive Officer & Executive Chairman | 2M | male |
| Feng Tian | CEO & Executive Director | 39.3K | male |
| Mark J. Gilbert | Senior Advisor & Acting Chief Medical Officer | — | male |
| Chunan Chen | Senior Vice President | — | male |
| Zhen Xia | Head of Clinical Science Department | — | female |
| Jihua Qin | Vice President and Head of Marketing & Medical Affairs | — | female |
| Ka Man Ng | Company Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2126.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
